Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Bafna Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Disclosure of Voting results of Postal Ballot
Bafna Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizer's Report. Standalone Financial Results, Limited Review Report for December 31, 2016
Bafna Pharmaceuticals Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Standalone Limited Review for the period ended December 31, 2016 Board Meeting Intimation for Results
Bafna Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on February 04, 2017, to consider among others, the Unaudited Financial Results for the quarter ended December 31, 2016. Updates
Bafna Pharmaceuticals Ltd has submitted to BSE a copy of Newspaper Advertisement(s) published in newspapers and on the Postal Ballot Notice sent to the shareholders in connection with issue of 80,00,000 warrants convertible to equity shares on preferential basis. Updates
Bafna Pharmaceuticals Ltd has submitted to BSE a copy of Newspaper Advertisement(s) published in newspapers on January 20, 2017 and on the Corrigendum to Postal Ballot Notice sent to the shareholders in connection with issue of 80,00,000 warrants convertible to equity shares on preferential basis. Corrigendum to postal ballot notice
Bafna Pharmaceuticals Ltd has informed BSE regarding "Corrigendum to Postal Ballot Notice dated 07.01.2017". Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Bafna Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended December 31, 2016
Bafna Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amri Bai Bafna